

Data Sheet

Product Name: Fmoc-Thr[GalNAc(Ac)3-α-D]-OH

Molecular Weight: 670.66

Target: Amino Acid Derivatives

Pathway: Others

Solubility: DMSO : ≥ 100 mg/mL (149.11 mM)

BIOLOGICAL ACTIVITY:

Fmoc-Thr[GalNAc(Ac)3-α-D]-OH i a building block in the development of cancer vaccine. *In Vitro*: The O-glycosidic linkage and the O-acetyl protection in this building block is stable to both piperidine and TFA, making it completely compatible with standard protocols in Fmoc solid phase peptide synthesis. The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser/Thr (Tn +antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide α- N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Galβ1-3GalNAcα1-OSer/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 β3-galactosyltransferase or C1GalT). Formation of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by *Cosmc* on the X-chromosome^[1].

References:

[1]. Ju T, et al. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 2014 Jan 1;14(1):63-81.

CAIndexNames:

 $L-Threonine, N-[(9H-fluoren-9-ylmethoxy) carbonyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-\alpha-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-a-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-a-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-a-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-a-D-galactopyranosyl]-O-[3,4,6-tri-O-acetyl-2-(acetyl-2-a$

SMILES:

 $O=C(N[C@H](C(O)=O)[C@@H](C)O[C@@H](C)C(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O)[C@@H]1NC(C)=O)OCC2C(C=CC=C3)=C3C4\\ =CC=CC=C24$

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite Q., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com